Sign up to our newsletter Subscribe
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we…
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we outline the major issues including the potential benefits of IBP, potential drawbacks, and considerations for implementation. We then ask for your views. To submit your thoughts, please access the survey which accompanies the Discussion Paper. Consultation closing date: Monday, 30 September 2019.
Although the science is in the middle of the process, we have made a difference. Increasingly, medicines will have multiple indications. New payment mechanisms are being proposed with the innovation landscape. One such mechanism is allowing the healthcare system to support different indications for a different indication of a medicine: indication-based pricing (IBP).
OHE previously launched a Discussion Paper (now also available in Spanish), which outlines the key potential benefits and drawbacks of IBP, along with considerations for implementation. This is accompanied by a consultation exercise , where we ask you to contribute your thoughts.
The consultation closes on Monday, 30 September 2019.
See below to access the survey in French.
…………………………………………………………………………………………………………………………………………………………………….
…………………………………………………………………………………………………………………………………………………………………….
Citation
Cole, A., Towse, A. and Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper . OHE Briefing, London: Office of Health Economics.
Related research
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M., 2015. Multi-indication pricing: pros, cons and applicability to the UK . OHE Seminar Briefing, Office of Health Economics.
Cole, A., Towse, A., Lorgelly, P. and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals . Research Paper, Office of Health Economics.
Towse, A., Cole, A. and Zamora, B., 2018. The Debate on Indication-Based Pricing in the US and Five Major European Countries . Consulting Report, Office of Health Economics.
Neri, M., Towse, A., and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward . OHE Briefing, Office of Health Economics.
An error has occurred, please try again later.
